CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Nov 14, 2022 4:05pm EST
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Nov 2, 2022 8:45am EDT
Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) Sep 28, 2022 • 1:00 pm EST
